29th August 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Cipla receives Form 483 from USFDA with six observations

The US Food and Drug Administration (USFDA) issued six observations to Cipla, a major pharmaceutical company, following an inspection of its Goa plant in August 2022.

GSK notifies Akums and Associate regarding the "Zinetac" brand

In order to stop selling ranitidine under the brand name “Zintac, ” Glaxosmithkline Pharmaceuticals has sent cease and desist letters to Akums Drugs and Pharmaceuticals (ADPL) and its affiliate Nicholas Healthcare.

Pharma company fined for discharging medical waste in public

A pharmaceutical company was issued a spot fine of Rs. 25,000 by the Indore Municipal Corporation for allegedly leaving medical waste lying around in the open.

Lupin introduces Desvenlafaxine ER Tablets in United States

Desvenlafaxine Extended-Release Tablets, 25 mg, have been made available by Lupin today after receiving approval from the US Food and Drug Administration (FDA).

Glenmark Pharmaceuticals declared a 2.50 dividend

Glenmark Pharmaceuticals Limited shareholders will be paid 2.50 per share on October 27th. Due to this payment, the dividend yield will be 0.7%, which is lower than the sector average.

Takeda terminates its microbiome alliance with Finch Therapeutics following review of its pipeline

Takeda Pharmaceutical and Finch Therapeutics’ microbiome partnership is coming to an end without either of the two joint inflammatory bowel disease research programs making it to human testing.

Bayer Begins Key Trials for Thrombosis Drug in Pipeline Revival

The German pharmaceutical company Bayer AG has begun pivotal late-stage studies of a new thrombosis prevention drug as it works to update a portfolio that is being threatened by low-cost generic competition.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?